Duration of Antibiotic Treatment for Foot Osteomyelitis in People with Diabetes.

IF 4.3 2区 医学 Q1 INFECTIOUS DISEASES
Meryl Cinzía Tila Tamara Gramberg, Bart Torensma, Suzanne van Asten, Elske Sieswerda, Louise Willy Elizabeth Sabelis, Martin den Heijer, Ralph de Vries, Vincent de Groot, Edgar Josephus Gerardus Peters
{"title":"Duration of Antibiotic Treatment for Foot Osteomyelitis in People with Diabetes.","authors":"Meryl Cinzía Tila Tamara Gramberg, Bart Torensma, Suzanne van Asten, Elske Sieswerda, Louise Willy Elizabeth Sabelis, Martin den Heijer, Ralph de Vries, Vincent de Groot, Edgar Josephus Gerardus Peters","doi":"10.3390/antibiotics13121173","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The optimal antimicrobial treatment duration for diabetes-related foot osteomyelitis (DFO) currently needs to be determined. We systematically reviewed the effects of short and long treatment durations on outcomes of DFO. <b>Methods:</b> We performed a systematic review searching Cochrane, CENTRAL, MEDLINE, Embase, and CINAHL Plus from inception up to 19 January 2024. Two independent reviewers screened the titles and abstracts of the studies. Studies comparing short (<6 weeks) and long (>6 weeks) treatment durations for DFO were included. The primary outcome was amputation; the secondary outcomes were remission, mortality, costs, quality of life, and adverse events. Risk of bias and GRADE were assessed. <b>Results:</b> We identified 2708 references, of which 2173 remained after removing duplicates. Two studies were included. Differences in methodology precluded a meta-analysis. The primary outcome, major amputation, was reported in one study, with a rate of 10% in both the intervention and comparison groups (<i>p</i> = 1.00), regardless of treatment duration. For the secondary outcome, remission rates, the first study reported 60% in the intervention group versus 70% in the comparison group (<i>p</i> = 0.50). In the second study, remission rates were 84% in the intervention group versus 78% in the comparison group (<i>p</i> = 0.55). Data for the outcomes mortality, costs, and quality of life were not available. Short treatment duration may lead to fewer adverse events. The risk of bias was assessed as low to moderate, and the level of evidence ranged from very low to moderate. <b>Conclusions:</b> Our findings suggest that for DFO, there is no difference between a shorter and more prolonged duration of antimicrobial treatment regarding amputation and remission, with potentially fewer adverse events with shorter treatment durations. However, the uncertainty stems from limited, heterogeneous studies and generally low-quality evidence marred by moderate biases, imprecision, and indirectness. More high-quality studies are needed to substantiate these findings.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"13 12","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672615/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics13121173","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The optimal antimicrobial treatment duration for diabetes-related foot osteomyelitis (DFO) currently needs to be determined. We systematically reviewed the effects of short and long treatment durations on outcomes of DFO. Methods: We performed a systematic review searching Cochrane, CENTRAL, MEDLINE, Embase, and CINAHL Plus from inception up to 19 January 2024. Two independent reviewers screened the titles and abstracts of the studies. Studies comparing short (<6 weeks) and long (>6 weeks) treatment durations for DFO were included. The primary outcome was amputation; the secondary outcomes were remission, mortality, costs, quality of life, and adverse events. Risk of bias and GRADE were assessed. Results: We identified 2708 references, of which 2173 remained after removing duplicates. Two studies were included. Differences in methodology precluded a meta-analysis. The primary outcome, major amputation, was reported in one study, with a rate of 10% in both the intervention and comparison groups (p = 1.00), regardless of treatment duration. For the secondary outcome, remission rates, the first study reported 60% in the intervention group versus 70% in the comparison group (p = 0.50). In the second study, remission rates were 84% in the intervention group versus 78% in the comparison group (p = 0.55). Data for the outcomes mortality, costs, and quality of life were not available. Short treatment duration may lead to fewer adverse events. The risk of bias was assessed as low to moderate, and the level of evidence ranged from very low to moderate. Conclusions: Our findings suggest that for DFO, there is no difference between a shorter and more prolonged duration of antimicrobial treatment regarding amputation and remission, with potentially fewer adverse events with shorter treatment durations. However, the uncertainty stems from limited, heterogeneous studies and generally low-quality evidence marred by moderate biases, imprecision, and indirectness. More high-quality studies are needed to substantiate these findings.

糖尿病患者足部骨髓炎的抗生素治疗时间。
背景:目前需要确定糖尿病相关性足部骨髓炎(DFO)的最佳抗菌治疗时间。我们系统地回顾了短期和长期治疗时间对DFO预后的影响。方法:我们对Cochrane、CENTRAL、MEDLINE、Embase和CINAHL Plus从成立到2024年1月19日进行了系统综述。两位独立的审稿人筛选了研究的标题和摘要。比较DFO治疗时间较短(6周)的研究被纳入。主要结局是截肢;次要结局是缓解、死亡率、费用、生活质量和不良事件。评估偏倚风险和GRADE。结果:共检索到文献2708篇,删除重复文献后剩余2173篇。纳入了两项研究。方法学的差异妨碍了meta分析。一项研究报告了主要结局,主要截肢,无论治疗时间长短,干预组和对照组的发生率均为10% (p = 1.00)。对于次要结果,缓解率,第一项研究报告干预组为60%,对照组为70% (p = 0.50)。在第二项研究中,干预组的缓解率为84%,对照组为78% (p = 0.55)。有关结果、死亡率、费用和生活质量的数据尚无。治疗时间短可减少不良事件。偏倚风险评估为低至中等,证据水平从极低到中等。结论:我们的研究结果表明,对于DFO,在截肢和缓解方面,较短的抗菌治疗时间和较长的抗菌治疗时间没有区别,较短的治疗时间可能更少的不良事件。然而,不确定性源于有限的、异质的研究和一般低质量的证据,这些证据受到中等偏倚、不精确和间接的损害。需要更多高质量的研究来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antibiotics-Basel
Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍: Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信